{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:14:26Z","timestamp":1784632466935,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Cerus Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Pathogen reduction technology using amustaline (S\u2010303) was developed to reduce the risk of transfusion\u2010transmitted infection and adverse effects of residual leucocytes. In this study, the viability of red blood cells (<jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s) prepared with a second\u2010generation process and stored for 35 days was evaluated in two different blood centres.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In a single\u2010blind, randomized, controlled, two\u2010period crossover study (<jats:italic>n<\/jats:italic> = 42 healthy subjects), amustaline\u2010treated (Test) or Control <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s were prepared in random sequence and stored for 35 days. On day 35, an aliquot of <jats:sup>51<\/jats:sup>Cr\/<jats:sup>99m<\/jats:sup>Tc radiolabeled <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s was transfused. In a subgroup of 26 evaluable subjects, 24\u2010h <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content> post\u2010transfusion recovery, mean life span, median life span (T<jats:sub>50<\/jats:sub>) and life span area under the curve (<jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>) were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean 24\u2010h post\u2010transfusion recovery of Test and Control <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s was comparable (83\u00b72 \u00b1 5\u00b72 and 84\u00b79 \u00b1 5\u00b79%, respectively; <jats:italic>P<\/jats:italic> = 0\u00b706) and consistent with the US Food and Drug Administration (<jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>) criteria for acceptable <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content> viability. There were differences in the T<jats:sub>50<\/jats:sub> between Test and Control <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s (33\u00b75 and 39\u00b77 days, respectively; <jats:italic>P<\/jats:italic> &lt; 0\u00b7001), however, these were within published reference ranges of 28\u201335 days. The <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content> (per cent surviving \u00d7 days) for Test and Control <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s was similar (22\u00b76 and 23\u00b71 per cent surviving cells \u00d7 days, respectively; <jats:italic>P<\/jats:italic> &gt; 0\u00b705). Following infusion of Test <jats:styled-content style=\"fixed-case\">RBC<\/jats:styled-content>s, there were no clinically relevant abnormal laboratory values or adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RBCs prepared using amustaline pathogen reduction meet the <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> criteria for post\u2010transfusion recovery and are metabolically and physiologically appropriate for transfusion following 35 days of storage.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12500","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:58:18Z","timestamp":1487689098000},"page":"210-218","source":"Crossref","is-referenced-by-count":37,"title":["Red blood cell concentrates treated with the amustaline (S\u2010303) pathogen reduction system and stored for 35 days retain post\u2010transfusion viability: results of a two\u2010centre study"],"prefix":"10.1111","volume":"112","author":[{"given":"J. A.","family":"Cancelas","sequence":"first","affiliation":[{"name":"Hoxworth Blood Center Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Gottschall","sequence":"additional","affiliation":[{"name":"BloodCenter of Wisconsin Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rugg","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Graminske","sequence":"additional","affiliation":[{"name":"BloodCenter of Wisconsin Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Schott","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"North","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Huang","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mufti","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rico","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Corash","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2005.04315.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2016.02.017"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13680"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12371"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620872"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13259"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2014.12.016"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12403"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02873.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02151.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265344.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(01)00117-3"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"816a","article-title":"Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates","volume":"102","author":"Dupuis K","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_15_1","first-page":"101a","article-title":"High titer leukocyte inactivation in INTERCEPT red blood cells (RBC) [abstract]","volume":"81","author":"Hanson D","year":"2001","journal-title":"Vox Sang"},{"key":"e_1_2_7_16_1","first-page":"36","article-title":"Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system [abstract]","volume":"8","author":"Mikovits JA","year":"2010","journal-title":"Rev Antivir Ther Infect Dis"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.10.019"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00973.x"},{"issue":"1","key":"e_1_2_7_19_1","first-page":"8","article-title":"A randomized, controlled, 2\u2010period crossover study of recovery and lifespan of radiolabeled autologous 35\u2010day old red blood cells prepared with a modified S\u2010303 treatment for pathogen inactivation [abstract]","volume":"95","author":"Cancelas JA","year":"2008","journal-title":"Vox Sang"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00583.x"},{"issue":"1","key":"e_1_2_7_21_1","first-page":"121","article-title":"S\u2010303 pathogen inactivated red blood cells in patients with hemoglobinopathies participating in chronic transfusion programs: preliminary safety and efficacy results [abstract]","volume":"89","author":"Conlan MG","year":"2005","journal-title":"Vox Sang"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.V104.11.382.382","article-title":"Antibody formation to S\u2010303\u2010treated RBCs in the setting of chronic RBC transfusion [abstract]","volume":"104","author":"Conlan MG","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03132.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03163.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00897.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24284173339.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1980.tb07189.x"},{"key":"e_1_2_7_28_1","unstructured":"HandinRI LuxSE StosselTP: (2003). Appendix 25 and 31.Blood: Principles and Practice of Hematology. Philadelphia Lippincott Williams & Wilkins: 2216 2219"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12562"},{"key":"e_1_2_7_30_1","first-page":"3","volume-title":"Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists","author":"Kwon Y","year":"2001"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1971.tb07068.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1974.tb00461.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24284173365.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T23:02:53Z","timestamp":1696028573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/vox.12500"],"URL":"https:\/\/doi.org\/10.1111\/vox.12500","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}